<DOC>
	<DOCNO>NCT01691807</DOCNO>
	<brief_summary>The purpose study evaluate potential drug-drug interaction ofatumumab bendamustine subject previously untreated relapsed indolent B-cell non-Hodgkin 's lymphoma ( NHL ) .</brief_summary>
	<brief_title>Drug-drug Interaction Study Ofatumumab With Bendamustine Subjects With Indolent B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>The purpose study evaluate potential drug-drug interaction ofatumumab bendamustine subject previously untreated relapsed indolent B-cell non-Hodgkin 's lymphoma ( NHL ) . Ofatumumab bendamustine administer alone combination two-arm , open-label study evaluate pharmacokinetic profile , safety , tolerability , efficacy ofatumumab bendamustine . The primary objective study evaluate pharmacokinetic parameter ofatumumab bendamustine alone combination . Secondary objective evaluate safety , tolerability , efficacy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Subjects previously untreated relapsed indolent Bcell NHL require treatment . Indolent NHL define small lymphocytic lymphoma ( SLL ) , lymphoplasmacytic lymphoma ( LPL ) , marginal zone lymphoma ( MZL ) , follicular lymphoma ( FL ) ; grade 1 , 2 , 3A , define accord WHO guideline . Tumor verify CD20+ positive previous current lymph node biopsy . At least 4 week previous anticancer chemotherapy , radiotherapy treatment . At least 12 week previous antiCD20 radioimmunotherapy , antiCD20 antibody treatment , nonantiCD20 monoclonal antibody treatment . Subjects give consent study participation sign inform consent form . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 . Age great equal 18 year informed consent . A female subject eligible participate Nonchildbearing potential require use contraception method . Male subject female partner childbearing potential must agree use contraception method . Subjects must agree use contraception 12 month last dose study drug . Subjects fail achieve complete remission ( CR ) partial remission ( PR ) progress within 6 month last rituximabcontaining therapy Previous treatment ofatumumab . Prior bendamustine treatment result complete remission partial remission least 6 month . Previous allogeneic stem cell transplant . Previous autologous stem cell transplant . High dose steroid great equal 100 mg prednisone/day ( equivalent ) great equal 7 consecutive day , give concomitant medication , within 3 month prior randomization . No 20 mg prednisone equivalent daily time randomization . Grade 3b follicular lymphoma evidence indolent lymphoma transform aggressive lymphoma verify biopsy confirmation . Known central nervous system involvement NHL . Other past current malignancy . Subjects free malignancy least 2 year , history definitively treat nonmelanoma skin cancer , successfully treat situ carcinoma , eligible . Chronic current active infectious disease require systemic antibiotic , antifungal , antiviral treatment , limited , chronic renal infection , chronic chest infection bronchiectasis , tuberculosis , active Hepatitis B C. Prophylactic antibiotic prevent recurrent prior infection ( shingle , sinusitis upper respiratory infection ) allow . Clinically significant cardiac disease judge investigator , include unstable angina , acute myocardial infarction within 6 month randomization , uncontrolled congestive heart failure ( CHF ) arrhythmia . Patients history CHF arrhythmia eligible cardiac disease well control stable medical regimen . History significant cerebrovascular disease event significant symptom sequela ( judged investigator ) . Significant concurrent , uncontrolled medical condition opinion investigator contraindicate participation study . Positive serology Hepatitis B ( HB ) define positive test Hepatitis B surface antigen ( HBsAg ) . In addition , negative HBsAg Hepatitis B core antibody ( HBcAb ) positive ( regardless Hepatitis B surface antibody [ HBsAb ] status ) , HB DNA test perform positive subject exclude . If HBV DNA negative , subject may include must undergo Hepatitis B virus ( HBV ) DNA monitoring ( see Section 7.7.5 ) . Prophylactic antiviral therapy may initiate discretion investigator . Current active liver biliary disease ( subject Gilbert 's syndrome asymptomatic gallstone , liver metastasis related indolent NHL otherwise stable chronic liver disease per investigator assessment , eligible ) . Known human immunodeficiency virus ( HIV ) positive . Screening laboratory value : platelet &lt; 100 x 109/L ( unless due lymphoma involvement bone marrow ) neutrophils &lt; 1.5 x 109/L ( unless due lymphoma involvement bone marrow ) serum creatinine &gt; 1.5 time institution 's upper limit normal ( ULN ) ; subject serum creatinine &gt; 1.5 ULN eligible calculate creatinine clearance [ Cockcroft , 1976 ] creatinine clearance 24hour urine collection â‰¥ 40 mL/min total bilirubin &gt; 1.5 time ULN ( unless due liver involvement lymphoma Gilbert 's syndrome ) transaminases &gt; 2 time ULN Known suspect hypersensitivity ofatumumab , bendamustine , mannitol . Treatment known nonmarketed drug substance experimental therapy within 5 terminal halflives 4 week prior Visit 1 , whichever longer currently participate interventional clinical study Lactating woman , woman positive pregnancy test Visit 1 , woman ( childbearing potential ) well men partner childbearing potential , willing use adequate contraception 12 month last dose study drug . Adequate contraception define Section 8.1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>drug-drug interaction</keyword>
	<keyword>ofatumumab</keyword>
	<keyword>bendamustine</keyword>
</DOC>